Sign up Australia
Proactive Investors - Run By Investors For Investors

Living Cell Technologies' shares slump 85% at the open

Results from the clinical trial were disappointing.
Living Cell Technologies' shares slump 85% at the open
Shares will fall at the open

Living Cell Technologies Ltd's (ASX:LCT) shares have plunged 85.4% to $0.03 on heavy volume in the first 15 minutes of trade, following the top-line results of the company's Parkinson’s trial.

The Phase IIb clinical study of NTCELL® for Parkinson’s disease have been unblinded.

Three of the four primary endpoints were met.

The company noted that at 26 weeks post implant, there is not a statistically significant difference between the groups who received NTCELL and the patients who had sham surgery, as measured by the change in the Unified Parkinson’s Disease Rating Scale (UPDRS Part III in the off state).

Dr Ken Taylor, chief executive officer, said that the company is disappointed in the results.

View full LCT profile View Profile

Living Cell Technologies Ltd Timeline

Related Articles

scientist with vial
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes
People working in a laboratory
May 02 2018
The benefits of Admedus' proprietary ADAPT technology and products are now scientifically proven beyond doubt.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use